Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- University of Illinois at Chicago
- Study ID
- NCT05051618
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- POWER-MS — BEHAVIORALThe POWER-MS intervention includes both aerobic exercise and resistance exercise: Aerobic Exercise: The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention. Resistance Exercise: Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level.
- FLEX-MS — BEHAVIORALThe FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
Study Details
The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants. This is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching program (FLEX-MS) for immediate and sustained reductions in the severity of depression among persons with MS who have MDD.
Key Dates
- Start date
- Apr 1, 2023
- Status verified
- Jun 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 146 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: POWER-MSThe POWER-MS condition will deliver the Guidelines for Exercise in MS (GEMS) program with a remotely coached/guided, home-based setting using telerehabilitation. GEMS recommends 30 minutes of moderate intensity aerobic activity, 3x/week AND strength training exercises for major muscle groups, 3x/week.
- Active Comparator: FLEX-MSThe FLEX-MS condition will primarily focus on flexibility as the applicable exercise modality. As such, the program will emphasize that flexibility is an important component of fitness. The goal would be for each participant to enhance their flexibility by engaging in a titrated exercise prescription where the number of sets and time to hold per set will increase throughout the 16-week program.
Primary Outcome Measure
Change in Depression Severity (self-report) [ Time Frame: baseline (week 0), immediate follow-up (week 16 or 4 months), and long-term follow-up (week 32 or 8 months) ]
Central Contacts
- Robert W Motl, PhD205-975-1306
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Illinois at Chicago | Chicago | Illinois | 60612 |
Find similar trials in Chicago, IL
Related Studies
- Quality Improvement and Practice Based Research in Neurology Using the EMRPHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- An Individualized-health eLibrary App for People With Multiple SclerosisRecruiting · University of Illinois at Urbana-Champaign · Champaign, Illinois
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut